{"filings":[{"id":528636,"accession_number":"0001493152-26-024438","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2026-05-19T20:54:13+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Enovis shareholders approve plan amendment adding 3.65M shares, raising director pay cap to $750k","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2020 Omnibus Incentive Plan adding 3,650,000 shares of common stock for issuance.","Outside director annual compensation limit increased from $350,000 to $750,000 (200% in first year).","All ten Board nominees elected; ratification of Ernst & Young as auditor passed; say-on-pay approved.","Plan amendment effective upon stockholder approval at May 19, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92760,"accession_number":"0001420800-26-000017","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q1 net sales up 5% to $589M, net loss $8M; reaffirms FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $589M (+5% reported, +3% organic); Recon sales +11% reported, P&R flat.","Net loss $8M (1.4% of sales), $0.15 per share; adjusted EPS $0.89; adjusted EBITDA $104M (17.6% of sales).","FY2026 guidance reaffirmed: revenue $2.31-2.37B, adjusted EBITDA $425-435M, adjusted EPS $3.52-$3.73.","Company cites solid execution, new product launches, but dynamic macroeconomic environment as factors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":589151000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103865,"accession_number":"0001420800-26-000008","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis posts FY2025 net loss of $1.18B including $1.05B goodwill impairment; Q4 sales $576M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net sales $2.2B, up 7% reported/6% organic; Recon sales +10%, P&R +4%.","Q4 net loss $519M includes $501M non-cash goodwill impairment; adjusted EPS $0.95.","Full-year adjusted EBITDA $403M; adjusted diluted EPS $3.30.","2026 guidance: revenue $2.31-2.37B (4-6% organic growth), adjusted EBITDA $425-435M, adjusted EPS $3.52-3.73.","CEO cites operational progress, Lima integration, and debt reduction; outlook reflects cautious macro view."],"consensus_eps_estimate":null,"consensus_eps_actual":-20.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2248049000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103864,"accession_number":"0001493152-26-001206","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enovis to present at J.P. Morgan Healthcare Conference; presentation materials furnished, no specific updates disclosed.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Management will present at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.","Presentation materials attached as Exhibit 99.1, but exhibit text not provided for detailed analysis.","No new financial or operational information disclosed; routine investor event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120137,"accession_number":"0001493152-25-027738","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Enovis CHRO Patricia Lang to retire; Laura Singleton appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patricia Lang will step down as SVP & CHRO effective April 3, 2026, transitioning to advisory role until April 3, 2027.","Laura Singleton, currently VP of HR for Reconstructive segment, to become SVP & CHRO on April 3, 2026.","Singleton joined Enovis in Feb 2019 via DJO Global acquisition; prior HR roles at Toppan Photomasks, Ixia, Millennium Labs.","Lang will receive current base salary for 6 months of advisory period, then reduced up to 50% through April 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120136,"accession_number":"0001493152-25-027007","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Enovis amends credit agreement; extends maturity to 2030, upsizes cash offset to $400M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended credit agreement provides $1.1B revolver and $700M term loan, both maturing Dec 8, 2030.","Repaid ~$335M of revolver with term loan proceeds; outstanding as of Dec 8: $167M revolver, $700M term loan.","Maximum cash offset for leverage calculations increased from $150M to $400M; acquisition consideration limit raised to $200M.","Covenant: temporary leverage increase available for acquisitions ≥$300M (previously $500M); new lenders added.","Applicable margin reduced for total leverage ratio below 1.50x; maturity conditional on liquidity vs. convertible notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120135,"accession_number":"0001493152-25-023418","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Enovis EVP Strategy & Business Dev Pryor steps down; advisory role through Mar 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel A. Pryor departed as EVP Strategy and Business Development on Nov 7, 2025; position eliminated.","Pryor remains an employee in advisory role through March 31, 2026 for transition services.","Separation agreement: continues base salary, benefits, 2025 bonus eligibility, and equity vesting through departure.","Post-departure severance: base salary plus larger of target bonus or avg of top two bonuses from prior 3 years.","Also receives 12-month health coverage continuation and outplacement assistance capped at $75,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120134,"accession_number":"0001420800-25-000038","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q3 sales up 9% to $549M; raises FY adjusted EBITDA and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $549M (+9% reported, +7% organic); Recon +12% reported, P&R +6% reported.","Net loss $571M including $548M non-cash goodwill impairment; adjusted EPS $0.75.","Divested Dr. Comfort (Diabetic Footcare) unit in Oct for up to $60M.","Raised FY2025 guidance: revenue $2.24-2.27B, adj. EBITDA $395-405M, adj. EPS $3.10-3.25."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":1672291000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136709,"accession_number":"0001420800-25-000029","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q2 revenue up 7%, guided FY25 higher; adjusted EPS $0.79","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $565M (+7% reported, +5% organic); Recon +11%, P&R +5%.","Net loss $37M ($0.64 loss/share); adjusted EBITDA $97M (17.2% of sales).","Adjusted diluted EPS $0.79; full-year adjusted EPS guidance raised to $3.05-3.20.","FY25 revenue outlook raised to $2.245-2.275B; adjusted EBITDA $392-402M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1123379000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153927,"accession_number":"0001193125-25-123977","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Enovis shareholders elect nine directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; For votes ranged from 49.6M to 50.4M shares (broker non-votes 1.7M each).","Ratification of Ernst & Young as independent auditor for FY2025: 51.6M For, 0.5M Against, 43K Abstain.","Non-binding advisory vote on executive compensation approved: 49.6M For, 0.9M Against, 48K Abstain (1.7M broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153926,"accession_number":"0001420800-25-000015","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q1 revenue +8% to $559M; adjusted EBITDA margin 17.7% (+160bps); appoints Damien McDonald CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $559M, +8% reported; Recon +11%, P&R +5% YoY.","Net loss from cont. ops $56M ($0.98 loss per share); adjusted EPS $0.81.","Adjusted EBITDA $99M (17.7% of sales, +160 bps vs Q1 2024).","Raised FY2025 rev guidance to $2.22-2.25B; lowered adj. EBITDA to $385-395M (incl. $20M tariff impact).","Appointed Damien McDonald as CEO effective May 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":558834000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153925,"accession_number":"0001193125-25-070882","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Enovis appoints Damien McDonald as CEO effective May 12; Q1 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Damien McDonald, former LivaNova CEO, appointed CEO effective May 12, 2025; succeeds retiring CEO Matt Trerotola.","Matt Trerotola will not stand for re-election; Sharon Wienbar named independent Chair of the Board.","McDonald receives $1M base salary, 125% target bonus, and $6.5M initial equity award (50% time-based, 50% performance-based).","Q1 2025 guidance reiterated: revenue $555-563M, adjusted EBITDA $97-100M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172578,"accession_number":"0001193125-25-054845","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Enovis CEO Trerotola signs retirement transition; will serve as Special Advisor for 1 year post-successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Matthew Trerotola's retirement effective when successor appointed; transition agreement signed March 13, 2025.","He will serve as Special Advisor for one year after Appointment Date, receiving current $1,077,000 base salary for two months then reduced (min 50%).","No further equity or long-term incentive awards; outstanding awards continue per retirement provisions in equity agreements.","Non-compete applies for two years after Retirement Date in orthopedic and medical device business; non-solicitation and non-disparagement also in place.","Successor CEO has not yet been named by the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172577,"accession_number":"0001420800-25-000007","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q4 net loss $704M on $645M goodwill impairment; CEO plans retirement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $561M (+23% reported, +6% comparable); Recon sales +59% reported.","Adjusted EBITDA $113M (20% of sales), +210 bps YoY; adj EPS $0.98 vs reported loss $12.06.","Full-year revenue $2.1B (+23% reported); adj EBITDA $377M (18% of sales).","2025 guidance: revenue $2.19-2.22B, adj EBITDA $405-415M, adj EPS $3.10-$3.25.","CEO Matt Trerotola to retire upon appointment of successor; board to lead search."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":2107623000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172576,"accession_number":"0001193125-25-035746","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Enovis CEO Matt Trerotola to retire; board begins search for successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Trerotola retiring upon successor appointment; will serve as Executive Advisor for one year.","Board engaged executive search firm to identify growth-oriented med-tech leader for CEO role.","Trerotola to address transition during Q4/FY2024 earnings call scheduled later today.","No successor named; transition planned as part of succession process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172575,"accession_number":"0001193125-25-013860","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Enovis files prospectus supplement to register 971,343 shares for resale by Emil","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Second tranche of 971,343 shares issued to Emil on Jan 15, 2025 as part of Lima acquisition consideration.","Shares registered for resale under the registration rights agreement; no new issuance or dilution.","Legal opinion from Latham & Watkins regarding legality of the securities attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172574,"accession_number":"0001193125-25-004929","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enovis to present at J.P. Morgan Healthcare Conference on Jan 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Matt Trerotola and CFO Ben Berry present at the conference at 9:45 AM PST.","Live webcast and replay available at www.enovis.com; presentation materials in Exhibit 99.1.","No specific operational or financial updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189567,"accession_number":"0001420800-24-000026","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q3 net sales $505M (+21% reported), adj. EPS $0.73 beat; raises FY adj. EPS guidance to $2.75-2.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $505M, up 21% reported/6% comparable; Recon sales +57% reported/9% comparable.","Net loss from continuing ops $0.61/sh; adjusted EPS $0.73, up 30% YoY.","Adjusted EBITDA $90M (17.9% of sales), margin +220 bps vs prior year.","FY2024 guidance: revenue ~$2.10B; adj. EBITDA $373-378M; adj. EPS raised from $2.62-2.77 to $2.75-2.80.","Lima acquisition contributed to Recon growth; integration progress cited."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":1546648000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206072,"accession_number":"0001420800-24-000019","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q2 sales up 23% to $525M; raises adjusted EPS guidance to $2.62-$2.77","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $525M (+23% reported, +5% comparable); Recon sales +60% reported.","Reported net loss from cont ops $0.34/sh; adjusted EPS $0.62; adj EBITDA $90M (17.2% of sales, +190bps).","Raised FY2024 adj EPS guidance to $2.62-$2.77 (from $2.52-$2.67); revenue narrowed to $2.08-$2.13B.","Received FDA 510k clearance for Arvis 2.0 Shoulder and Altivate Reverse Glenoid; launches expected Q3 2024.","Opened new manufacturing facility in San Daniele and Business Technology Center in Lisbon."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1041426000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206071,"accession_number":"0001193125-24-181063","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Enovis files resale registration for 971,343 shares issued to former Lima shareholder","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement for resale of 971,343 shares of common stock held by Emil Holding II.","Shares issued on July 16, 2024 as first tranche of consideration for LimaCorporate acquisition.","Second tranche of up to 971,343 shares expected to be issued in Q1 2025, subject to conditions.","Registration covers only the first tranche; no change to business operations or financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223102,"accession_number":"0001193125-24-144942","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Enovis stockholders approve 2.1M share increase to incentive plan and officer exculpation charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment adding 2,100,000 shares to the 2020 Omnibus Incentive Plan for future awards.","Charter amendment to permit officer exculpation under DGCL approved; filed with Delaware Secretary of State on May 22, 2024.","All 10 director nominees elected, including Matthew L. Trerotola and Barbara W. Bodem, with voting results provided.","Ratified Ernst & Young as independent auditor for FY2024 and approved advisory say-on-pay proposal.","Charter amendment passed with 42.3M for, 4.8M against; plan amendment passed with 45.6M for, 1.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223101,"accession_number":"0001420800-24-000009","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q1 revenue $516M (+27% YoY), adjusted EPS $0.50, raises full-year outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $516M, up 27% reported and 5% proforma YoY; Recon sales +66% reported, +7% proforma.","GAAP net loss from continuing ops $72M ($1.32/share loss); adjusted EPS of $0.50.","Adjusted EBITDA $83M (16.1% of sales), margin expanded 220 bps YoY.","Updated FY2024 guidance: revenue $2.06-2.16B, adj EBITDA $368-383M, adj EPS $2.52-$2.67.","Closed LimaCorporate acquisition; launched Arvis 2.0 and other products at AAOS."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":516266000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242602,"accession_number":"0001420800-24-000004","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q4 sales $455M +11% YoY; FY2024 guidance $2.05-2.15B revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net sales $455M (+11% YoY, organic +8%); net income $3M ($0.05 GAAP EPS), adjusted EPS $0.79.","Full year net sales $1.7B (+9% YoY, organic +8%); net loss $54M ($1.00 GAAP loss), adjusted EPS $2.40.","Recon segment Q4 revenue +18% (organic +11%); P&R Q4 +8% (organic +6%); full-year Recon +18%, P&R +5%.","Acquired LimaCorporate for ~€800M (closed Jan 3, 2024); 2024 forecast includes $290-300M Lima revenue.","2024 outlook: revenue $2.05-2.15B, adjusted EBITDA $365-380M, adjusted EPS $2.50-$2.65."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":1707197000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242599,"accession_number":"0001193125-24-041540","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K/A","filed_at":"2024-02-21T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Enovis files Lima financials post-acquisition: 2022 revenue €245.7M, net loss €19.3M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of LimaCorporate S.p.A. on Jan 3, 2024 from Emil Holding II S.à r.l.","Lima audited 2022 restated: €245.7M revenue, €4.7M operating loss, €19.3M net loss (2021: €210.5M revenue, €2.5M loss).","Lima total assets €753.9M at Dec 31, 2022; equity €306.6M, net financial debt €320.9M (€320.9M current + €10.2M non-current).","Pro forma combined financials as of Sep 30, 2023 filed as Exhibit 99.3; acquisition financed with debt and equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242601,"accession_number":"0001193125-24-003983","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enovis CEO/CFO to present at J.P. Morgan Healthcare Conference; slide content not detailed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Matt Trerotola and Ben Berry present at JP Morgan Healthcare Conference on Jan 8, 2024.","Presentation materials attached as Exhibit 99.1; substantive content not reproduced in 8-K text.","Webcast available on Enovis website; replay link provided later.","No specific financial data or guidance disclosed in the filing itself.","Filing is under Regulation FD; slides furnished but not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242600,"accession_number":"0001193125-24-000976","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Enovis Corp closes acquisition of LimaCorporate for ~€727M cash plus 1.94M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed acquisition of LimaCorporate on Jan 3, 2024 for ~€726.8M cash plus 1,942,686 shares valued at €100M.","Acquisition financed with term loan facility and proceeds from 3.875% convertible senior notes due 2028.","Lima adds 3D-printed Trabecular Titanium implants and comprehensive shoulder revision portfolio.","Enovis' recon segment to reach $1B in revenue, accelerating global growth and margin expansion.","CEO Matt Trerotola highlights strategic acquisition to drive compounding value for shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259983,"accession_number":"0001193125-23-289248","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Enovis COO Brady Shirley to retire by Q1 2025; Vogt and Ross promoted to Group Presidents","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brady Shirley to step down as President and COO on April 1, 2024, become Executive Advisor focused on Lima integration until retirement end of Q1 2025.","Louie Vogt promoted to Group President of Reconstructive segment effective Jan 2, 2024, reporting to CEO.","Terry Ross promoted to Group President of Prevention & Recovery segment effective Jan 2, 2024, reporting to CEO.","Shirley will remain on the Board of Directors during his transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259982,"accession_number":"0001420800-23-000028","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q3 sales $418M (+9% YoY), adj EPS $0.56; raises full-year outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $418M, +9% YoY; net loss from cont ops $19M ($0.36 loss per share).","Adjusted EPS $0.56; adjusted EBITDA $65M (15.7% of sales), +80 bps YoY.","Recon sales +16% (organic +10%), P&R +5% (organic +4%); US hip/knee +18%.","Full-year outlook raised: revenue organic growth 7.4-7.6%, adj EPS $2.30-$2.40.","Pending LimaCorporate acquisition (€800M EV) remains on track."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":1252177000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259981,"accession_number":"0001193125-23-262988","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Enovis issues $460M 3.875% convertible notes due 2028; net proceeds ~$445.1M for LimaCorporate acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$460M 3.875% convertible notes due Oct 2028 issued; net proceeds ~$445.1M after fees.","~$62M of net proceeds used for capped call transactions to reduce dilution upon conversion.","Remaining proceeds plus $400M term loan and cash will fund LimaCorporate acquisition announced Sep 25, 2023.","Credit agreement amended to add $400M secured term loan facility maturing Apr 2027 with senior secured leverage covenant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259980,"accession_number":"0001193125-23-259551","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Enovis prices $400M of 3.875% convertible notes due 2028 to fund Lima acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced $400M aggregate principal of 3.875% Convertible Senior Notes due 2028; initial purchasers option for additional $60M.","Initial conversion price ~$58.32/share (~30% premium to Oct 19 close); net proceeds ~$386.9M.","Proceeds, with ~$400M term loan and cash, to fund pending LimaCorporate acquisition; ~$53.9M used for capped call transactions.","Notes mature Oct 15, 2028; interest payable semiannually; if Lima deal fails by June 30, 2024, Enovis may redeem at 101%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259979,"accession_number":"0001193125-23-258915","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Enovis Q3 prelim revenue $414-$418M, adj EBITDA $64-$66M, +8-9% and +12-15% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue expected $414-$418M vs $383M prior year (+8-9%); adj EBITDA $64-$66M vs $57M (+12-15%).","Net loss from continuing ops $(20.1)-$(19.4)M; GAAP tax rate 23-24.2%. Reconciliation provided.","Announces proposed convertible senior notes due 2028 in private placement to QIBs.","Furnishes audited 2022 financials of acquisition target LimaCorporate: revenue €245.7M, net loss €19.3M.","Lima 2022 net loss includes €16.2M impairment; goodwill €384M, equity €306.6M. Pro forma combined statements provided."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":1252177000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277260,"accession_number":"0001193125-23-245630","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Enovis agrees to acquire LimaCorporate for ~€800M enterprise value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enterprise value ~€800M: ~€700M cash at closing plus 1,942,686 Enovis shares valued at €100M.","LimaCorporate is a privately held global orthopedic company specializing in digital innovation and custom hardware.","Closing expected in early 2024, subject to regulatory approvals (including Italian golden power) and other customary conditions.","Enovis obtained an $800M senior bridge facility commitment from JPMorgan and UBS to finance the acquisition.","Shares issued to the seller (Emil Holding II) will carry resale registration rights; issued within 18 months post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277259,"accession_number":"0001193125-23-240882","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enovis to acquire LimaCorporate for €800M enterprise value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enterprise value €800M: €700M cash at closing + €100M in Enovis common shares within 18 months.","Expected 2024 revenue $290-300M and adjusted EBITDA $70-75M from Lima.","Approximately $40M in cost synergies targeted by year three post-close via supply chain and cost consolidation.","Transaction expected to close early 2024, subject to regulatory approvals; neutral to slightly accretive to 2024 adjusted EPS.","Deal creates ~$1B revenue reconstruction business with ~50% in fast-growing extremities markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277258,"accession_number":"0001193125-23-232965","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enovis presents at Baird Global Healthcare Conference; no material new info disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Matt Trerotola and CFO Ben Berry presented at Baird Global Healthcare Conference on Sept 12, 2023.","Presentation materials were attached but the exhibit excerpt contains only names and titles, no financial data.","No specific operational or financial updates were provided in the filing text beyond the conference participation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277257,"accession_number":"0001420800-23-000021","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q2 sales up 8% to $429M; raises full-year guidance on organic growth and margin expansion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $429M, +8% YoY; organic sales per day growth 9%.","Reconstructive segment grew 18% (17% organic); Prevention & Recovery grew 4%.","Net loss from continuing ops $0.27 per share; adjusted EPS $0.61.","Full-year 2023 guidance raised: organic revenue growth now 7-7.5% (prev 6-7%), adjusted EBITDA $262-270M.","Adjusted EBITDA margin improved 110bps to 15.3% of sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":834653000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295148,"accession_number":"0001193125-23-150464","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Enovis shareholders approve stock purchase plan, elect directors, set say-on-pay frequency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the 2023 Non-Qualified Stock Purchase Plan, authorizing up to 1,000,000 shares of common stock.","All ten director nominees elected with majority votes, including Matthew Trerotola and Barbara Bodem.","Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year 2023.","Advisory vote on executive compensation approved (47.5M for, 1.2M against); frequency set to every year.","Say-on-pay frequency set to one year; next advisory vote scheduled for 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295147,"accession_number":"0001420800-23-000012","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q1 net sales $406M (+9% organic), adj EPS $0.44; raises FY2023 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Recon segment organic growth 19% (P&R +4%); total organic sales +9%.","Adjusted EBITDA $56M (13.9% of sales, +120 bps YoY); net loss from cont ops $0.42/sh.","FY 2023 outlook raised: organic rev growth 6-7% (prev 5-6%), adj EBITDA $259-267M, adj EPS $2.18-2.32.","Agreement to acquire Novastep (bunion segment) expected to close Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":406151000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315722,"accession_number":"0001193125-23-071411","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Enovis announces board leadership transition: Rales retiring, Trerotola to become Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mitchell P. Rales will not stand for re-election; retires as Chair at May 16, 2023 Annual Meeting.","CEO Matt Trerotola to become Chair of the Board effective May 16, 2023.","Sharon Wienbar to become Lead Independent Director; Board size reduces from 11 to 10.","Angela Lalor becomes Chair of Compensation and Human Capital Management Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315721,"accession_number":"0001420800-23-000003","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q4 net loss $0.71/sh, adj EPS $0.72; FY22 sales up 10% to $1.6B; guides FY23 adj EPS $2.15-2.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $409M (+2% YoY, +5% organic); Reconstructive segment organic growth 14%.","Q4 adj EBITDA $75M (18.3% of sales), +290 bps YoY; full-year adj EBITDA margin 15.1% (+70 bps).","FY22 net loss from continuing ops $38M ($0.25/diluted); adj EPS $2.27, up 15% YoY.","FY23 guidance: organic revenue growth 5-6%, adj EBITDA $255-265M, adj EPS $2.15-2.30.","Acquired Insight Medical Systems (ARVIS augmented reality) in 2022; acquisitions delivered double-digit organic growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":1563101000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315720,"accession_number":"0001193125-23-000880","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO transition finalized: Hix retires, Berry starts Jan 1, 2023 with $500K base","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hix retired as EVP/CFO Dec 31, 2022; stays in non-executive role through 2023 at $300K base salary.","Ben Berry appointed CFO effective Jan 1, 2023; base salary $500K, target bonus 75% of base.","Berry eligible for Feb 2023 equity grant with aggregate target value of $1,200,000.","Transition and compensation terms set in Hix retirement agreement and Berry offer letter filed with 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334068,"accession_number":"0001193125-22-305953","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2022-12-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Enovis amends bylaws to align with Delaware law, update stockholder meeting procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended bylaws align notice of adjournment and stockholder list availability with recent DGCL amendments.","Clarified procedures for stockholders to propose business or nominations at annual/special meetings, with additional disclosure requirements.","Addressed universal proxy rules: requires stockholder nominators to state intent to solicit proxies and provide compliance evidence.","Requires disclosures in stockholder nomination or proposal notices be updated as of record date and 10 business days before meeting.","Adopted technical, conforming, and modernizing changes including proxy card color rule for stockholders soliciting proxies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334067,"accession_number":"0001420800-22-000023","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Enovis exchanges retained ESAB shares for $230.5M of term loan debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Nov 18, 2022, Enovis exchanged 6,003,431 ESAB shares (all retained) for $230,531,750.40 of term loan.","The term loan is under the Credit Agreement dated April 4, 2022; original balance was $450M.","Transaction reduces Enovis's term loan debt by ~51%, leaving $219.5M outstanding.","Exchange counterparty was lender Goldman Sachs & Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334066,"accession_number":"0001420800-22-000020","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q3 revenue $384M (+7% organic), adj EPS $0.59 (+34% YoY), guides FY adj EPS $2.20-$2.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reconstructive segment revenue $127M (+15% organic); Prevention & Recovery $257M (+4% organic).","Reported net loss from continuing ops $(66)M ($(1.22)/diluted share); adjusted EPS grew to $0.59.","Adjusted EBITDA $57M (14.9% of sales); core margins improved 40 bps despite inflation.","FY 2022 outlook: organic growth ~6.5%, total sales growth ~10%, adj. EBITDA $235-$240M.","Launched EMPOWR 3D Knee in Europe and two connected bracing products for Motion iQ platform."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":1154388000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351481,"accession_number":"0001193125-22-228510","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2022-08-24T23:59:59+00:00","items":["5.04","9.01"],"status":"ready","headline":"Enovis imposes trading blackout Sept 23–Oct 14 due to 401(k) platform migration","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Blackout runs from Sept 23 (4:00 PM ET) to Oct 14 (8:00 AM ET) for plan participants and Section 16 officers.","Blackout needed to migrate the Enovis 401(k) Savings Plan Plus to a new recordkeeping platform.","Directors and officers prohibited from trading Enovis stock acquired via service during the BTR blackout period.","Changes to blackout dates will be communicated promptly; actual dates available from Corporate Secretary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351480,"accession_number":"0001420800-22-000016","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q2 revenue $395M (+11%), adjusted EPS $0.59 (+44%), full-year guidance updated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported EPS from continuing ops $2.21; adjusted EPS $0.59 vs $0.41 YoY, includes ~$0.10 one-time tax benefit.","Organic growth 3% (5% per-day); adjusted EBITDA $56M, +11% YoY, with $2M currency pressure.","Completed acquisitions of Insight Medical Systems (ARVIS AR surgical guidance) and 360 Med Care (Australian distributor).","Updated FY2022 outlook: organic growth 6-9% reaffirmed; adjusted EBITDA $235-255M; adjusted EPS $2.15-$2.35.","Currency headwinds expected to impact full-year; Q2 tax planning benefit lifted adjusted EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":770574000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368850,"accession_number":"0001193125-22-185624","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Enovis announces CFO transition: Hix to retire, Berry to succeed Jan 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Hix to retire as CFO on Dec 31, 2022; will remain as advisor until late 2023.","Ben Berry, current CFO of Enovis business units, to become CFO on Jan 1, 2023.","Berry joined Enovis in 2020, previously CFO of medtech segment; prior 18 years at Alcon.","Hix served as CFO since 2016, led portfolio transformation into pure-play medtech company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368849,"accession_number":"0001193125-22-172913","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Enovis shareholders approve 745,000-share increase to 2020 omnibus incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment adding 745,000 shares to the 2020 Omnibus Incentive Plan, total now 2,221,666.","Eleven directors elected, with all nominees receiving majority support; highest vote count was Christine Ortiz at ~48.7M.","Ratification of Ernst & Young as independent auditor for 2022 approved (49.66M for, 0.38M against).","Advisory vote on executive compensation passed with 47.24M for and 1.48M against.","Plan amendment itself approved with 46.84M for and 1.88M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368848,"accession_number":"0001193125-22-145678","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enovis reports Q1 adjusted stand-alone sales up 21% to $375M, EBITDA up 25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales of $375M (+21% total, +7% organic); Recon +72% (+12% organic), P&R +4% (+6% organic).","Adjusted stand-alone EBITDA of $48M (margin 12.7%, +40bps YoY); adjusted EPS $0.37.","Reaffirmed FY2022 guidance: revenue growth 10-14%, EBITDA $245-265M, EPS $2.20-2.40.","Completed spin-off of ESAB on April 4; strong balance sheet with near zero net leverage."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1023368000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368847,"accession_number":"0001193125-22-100359","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["1.01","2.01","2.03","3.03","5.03","5.02","8.01","9.01"],"status":"ready","headline":"Enovis completes ESAB spin-off; new $1.8B credit facility; board refreshed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On April 4, 2022, Enovis distributed 90% of ESAB shares: 1 ESAB per 3 Enovis shares; retained 10%.","Enovis entered new $900M revolver and $900M term loan; repaid prior debt and funds general corporate purposes.","On April 7, Enovis redeemed €350M 3.25% notes due 2025 and $300M 6.375% notes due 2026 with Separation proceeds.","Directors Allender, Jordan, Teirlinck resigned to ESAB board; Bodem, Lalor, Ortiz, Shirley appointed to Enovis board.","Name changed from Colfax to Enovis; 1-for-3 reverse stock split effected; stock trades under ENOV as of April 5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388088,"accession_number":"0001193125-22-074718","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Colfax sets April 4, 2022 for ESAB spin-off; reverse split 1:3 and name change to Enovis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date March 22, 2022; each CFX holder gets one ESAB share per three CFX shares held.","When-issued trading of ESAB (symbol ESAB WI) begins March 21; regular-way ESAB trading starts April 5.","Colfax retains 10% of ESAB; intends to divest within 12 months via tax-efficient debt exchange.","After distribution, CFX does 1:3 reverse stock split, name changes to Enovis (symbol ENOV).","Distribution expected to be tax-free for U.S. shareholders except cash for fractional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-14T23:59:59+00:00|388088"}